πŸ‡ΊπŸ‡Έ FDA
Patent

US 7772250

Compounds

granted A61PA61P11/00A61P11/06

Quick answer

US patent 7772250 (Compounds) held by Theravance, Inc. expires Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Aug 10 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 05 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P11/00, A61P11/06, A61P11/08, A61P15/06